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FIGHTING FOR YOUR LIFE IN AMERICA:    
A STUDY OF “RIGHT TO TRY” LAWS 
THROUGHOUT THE COUNTRY 
DANIELLE DELGROSSO† 
INTRODUCTION 
On June 9, 2011, cancer took the life of twenty-one-year-old 
Abigail Burroughs.1  Abigail spent the final seven months of her 
life fighting for access to an experimental drug, Erbutrix, not yet 
approved by the Food and Drug Administration (“FDA”) that her 
treating physician and family believed could save her life.2  Her 
efforts were unsuccessful.3 
Abigail’s death spawned the Abigail Alliance, a non-profit 
advocacy organization working for FDA regulatory changes that 
would allow terminally ill patients access to experimental drugs.4  
Spear-headed by Abigail’s father, Frank Burroughs,5 the Alliance 
has made noise in the media,6 in the courtroom,7 and on Capitol 
Hill.8  The commotion prompted “Right to Try” legislation to be  
 
 
† Notes & Comments Editor, St. John’s Law Review; J.D. Candidate, 2018, St. 
John’s University School of Law; B.A. English Literature, 2014, University of North 
Carolina at Wilmington. With thanks to Professor Anita S. Krishnakumar for her 
guidance and support in writing this Note, Professor Heather M. Butts for her 
mentorship, and the entire St. John’s Law Review editorial board for its dedication 
during this process. 
1 Frank Burroughs, Our Story, ABIGAIL ALLIANCE, http://www.abigail-alliance.o 
rg/story.php (last visited Dec. 27, 2017). 
2 Sue Kovach, The Abigail Alliance: Motivated by Tragic Circumstances, 
Families Battle an Uncaring Bureaucracy, LIFE EXTENSION 26 (2007), http://www.ab 
igail-alliance.org/LEMSEP07pAbigailLR.pdf. 
3 Id. 
4 Id. For purposes of this Note, the term “experimental drug[s]” refers to 
experimental drugs, biological products, or devices. 
5 Burroughs, supra note 1. 
6 See Kovach, supra note 2, at 30. 
7 See Abigail All. for Better Access to Developmental Drugs v. Von Eschenbach, 
495 F.3d 695 (D.C. Cir. 2007). 
8 Kovach, supra note 2, at 29. 
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passed in thirty-two states,9 and proposed in sixteen others.10  In 
May of 2016, a federal “Right to Try” bill was proposed in 
Congress.11  Problematically, not all of these laws look the same. 
Congress’s bill, the Trickett Wendler Right to Try Act of 2016 
(“the Trickett Wendler Act”),12 is named after a young mother of 
three who lost her battle against Amyotrophic Lateral Sclerosis 
(“ALS”) in March of 2015.13  Trickett and Abigail have similar 
stories.  Both suffered from conditions that would ultimately take 
their lives,14 were treated with drugs that could not and did not 
save them,15 and were denied access to unapproved drugs.16  Had 
the Trickett Wendler Act been law while Trickett or Abigail were 
alive, their stories may have had different endings. 
This Note argues that there should be a federal statute 
granting terminally ill patients access to experimental drugs, but 
that the Trickett Wendler Act, as written is not the proper 
vehicle for change.  An ideal congressional “Right to Try” statute 
 
9 Lenore Skenazy, Opinion, The Dying Deserve a Last Chance at Life, 
TIMESLEDGER NEWSPAPERS, Dec. 22, 2016. 
10 Editorial, Right-to-Try, COURIER (Northwestern Ohio) (Dec. 14, 2016), http:// 
thecourier.com/opinion/couriers-view/2016/12/14/right-to-try/. 
11 See S. 2912, 114th Cong. (2016); see also Trickett Wendler Right to Try Act of 
2016, CONGRESS.GOV, https://www.congress.gov/bill/114th-congress/senate-bill/2912 
?q=%7B%22search%22%3A%5B%22s+2912%22%5D%7D&r=1 (last visited Dec. 27, 
2017). 
12 S. 2912 114th Cong. (2016). In January 2017, a revised version of S.2912 was 
introduced in and subsequently passed by the Senate. See S. 204, 115th Cong. (2017) 
(The Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina 
Right to Try Act of 2017). In February, 2017, yet another version was introduced in 
the House. See H.R. 878, 115th Cong. (2017) (Right to Try Act of 2017). While this 
Note focuses exclusively on S. 2912, its analysis applies to all versions. 
13 Jenna Sachs, Fighting for the “Right to Try:” 14 Months After Her Death from 
ALS, Trickett Wendler’s Legacy Taking Shape, FOX6 NEWS (MILWAUKEE) (May 17, 
2016, 9:56 PM), http://fox6now.com/2016/05/17/fighting-for-the-right-to-try-14-month 
s-after-her-death-from-als-trickett-wendlers-legacy-taking-shape/. 
14 Id. (“ALS has no treatment, no cure, no survivors . . . .”); Sean Alfano, 
Fighting for a Miracle, CBS NEWS (Nov. 13, 2005, 3:26 AM), http://www.cbsnew 
s.com/news/fighting-for-a-miracle/ (reporting that Abigail knew early that her 
situation was hopeless). 
15 Joseph Gulfo, A Hearing Brought to Tears over Right to Try Legislation, THE 
HILL (May 17, 2016, 7:00 AM), http://thehill.com/blogs/pundits-blog/healthcare/2801 
27-a-hearing-brought-to-tears-over-right-to-try-legislation (explaining that Trickett’s 
current treatment would slow the process of her disease, but would not cure it); 
Burroughs, supra note 1 (stating that Abigail had run out of conventional options). 
16 Ann-Elise Henzl, Terminally Ill Patients and Their Loved Ones Push for 
Greater Access to Experimental Drugs, UW-MILWAUKEE: MILWAUKEE PUBLIC MEDIA 
(May 11, 2016), http://wuwm.com/post/terminally-ill-patients-and-their-loved-ones-
push-greater-access-experimental-drugs#stream/0; see also Burroughs, supra note 1. 
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should be crafted to make experimental drugs realistically 
obtainable for terminally ill patients while protecting those 
patients and their quality of life.  The Trickett Wendler Act’s 
weaknesses prevent it from reaching this objective because it is 
too deferential to already unclear state Right to Try laws.  Part I 
explores the right to try movement generally, explaining what a 
“right to try” is and the obstacles currently standing in its way.  
Part II examines and critiques different “Right to Try” laws that 
have been adopted in the states.  Part III proposes a model 
congressional “Right to Try” bill. 
I. THE RIGHT TO TRY 
Essentially, “Right to Try” laws provide terminally ill 
patients with access to experimental treatments that have 
successfully passed the first of the FDA’s three phases of clinical 
trials.17  According to FDA guidelines, a drug normally cannot go 
to market until it has successfully passed a phase-three trial.18  It 
is only at this point that the drug is considered safe and effective 
for human consumption.19  Right to Try laws effectively bypass 
the FDA’s system, allowing access to a drug before it receives the 
FDA’s stamp of approval.20  Right to Try proponents say this will 
reduce terminal patients’ waiting time for drugs not yet 
approved21—time that they simply do not have. 
 
17 CHRISTINA CORIERI, GOLDWATER INST., EVERYONE DESERVES THE RIGHT TO 
TRY: EMPOWERING THE TERMINALLY ILL TO TAKE CONTROL OF THEIR TREATMENT 1 
(Feb. 11, 2014), https://goldwater-media.s3.amazonaws.com/cms_page_media/2015/1/ 
28/Right%20To%20Try.pdf; Kimberly Leonard, Seeking the Right to Try, U.S. NEWS 
(Nov. 18, 2014, 12:01 AM), http://www.usnews.com/news/articles/2014/11/18/right-to-
try-laws-allowing-patients-to-try-experimental-drugs-bypass-fda. 
18 The FDA’s Drug Review Process: Ensuring Drugs are Safe and Effective, U.S. 
FOOD & DRUG ADMIN., http://www.fda.gov/drugs/resourcesforyou/consumers/ucm 
143534.htm (last updated Nov. 24, 2017) [hereinafter FDA Drug Review Process]; 
Conducting Clinical Trials, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/drugs 
/developmentapprovalprocess/conductingclinicaltrials/default.htm (last updated 
June 15, 2016) (“Clinical trials are an integral part of new product discovery and 
development and are required by the Food and Drug Administration before a new 
product can be brought to the market.”). 
19 FDA Drug Review Process, supra note 18. 
20 Leonard, supra note 17. 
21 Matthew Bellina, FDA Should Allow Treatment of Terminally Ill Patients 
with Experimental Drugs, WASH. POST: POWER POST (Sep. 28, 2016, 10:17 AM), 
https://www.washingtonpost.com/news/powerpost/wp/2016/09/28/fda-should-allow-
treatment-of-terminally-ill-patients-with-experimental-
drugs/?utm_term=.1d7591d80ec4. 
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State Right to Try laws embrace the belief that it is a 
terminally ill patient’s fundamental right to access unapproved 
drugs.22  At the heart of that belief is the idea that a person has 
the fundamental right to try to save his or her own life.23  
Advocates’ bottom line is that individuals should not have to ask 
the government for permission to survive.24 
However, there are three chief obstacles to Right to Try laws’ 
success: (1) there is no recognized constitutional right to try; 
(2) state Right to Try laws are federally preempted by FDA 
guidelines; and (3) there is no consensus as to whether a right to 
try should exist.  
First, despite proponents’ assertions that the terminally ill 
have a fundamental right to access investigational drugs, courts 
have not agreed.25  In Abigail Alliance v. Eschenbach, the United 
States Court of Appeals for the District of Columbia Circuit 
stated that, “such rights are not set forth in the language of the 
Constitution,” and “there is no fundamental right ‘deeply rooted 
in this Nation’s history and tradition’ of access to experimental 
drugs for the terminally ill.”26 
Second, the United States Constitution’s Supremacy Clause 
disallows any state law that contravenes a federal statute or 
statutorily authorized federal regulation.27  Such a state law is 
 
22 Rebecca Dresser, The “Right to Try” Investigational Drugs: Science and 
Stories in the Access Debate, 93 TEX. L. REV. 1631, 1640 (2015) (It is “the 
fundamental right of people to save their own lives”) (quoting CORIERI, supra note 
17, at 1). 
23 Id. 
24 See id. 
25 Alexandra Tsakopoulos, et al., Note, The Right to Try: An Overview of Efforts 
To Obtain Expedited Access to Unapproved Treatment for the Terminally Ill, 70 
FOOD & DRUG L.J. 617, 620 (2015). 
26 Abigail All. for Better Access to Developmental Drugs v. Von Eschenback, 495 
F.3d 695, 697, 702 (D.C. Cir. 2007) (quoting Washington v. Glucksberg, 521 U.S. 
702, 720–21 (1997)), cert. denied, 552 U.S. 1159 (2008). The Supreme Court, denying 
certiorari, has not directly answered this question. Thus, it remains possible that 
eventually the Supreme Court will opine that such a fundamental right exists. As of 
today, access to experimental drugs is not considered a fundamental right. 
27 U.S. CONST. art. VI, cl. 2 (“This Constitution, and the Laws of the United 
States which shall be made in Pursuance thereof . . . shall be the supreme Law of 
the Land; and the Judges in every State shall be bound thereby, any Thing in the 
Constitution or Laws of any State to the Contrary notwithstanding.”). See also 
Caitlyn Martin, Note, Questioning the “Right” in State Right to Try Laws: Assessing 
the Legality and Effectiveness of These Laws, 77 OHIO ST. L.J. 159, 178 (2016) (citing 
to Maryland v. Louisiana, 451 U.S. 725, 746 (1981); McCulloch v. Maryland, 17 U.S. 
316, 427 (1819); City of New York v. FCC, 486 U.S. 57, 63–64 (1988)). 
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preempted, or trumped, by the federal statute or regulation, 
making the state law ineffective.28  Although the question of 
whether or not state Right to Try laws are federally preempted 
has not been answered definitively, they are most likely trumped 
by FDA guidelines. 
The FDA derives its authority to regulate the premarket 
drug approval process from the Food, Drug, and Cosmetic Act 
(“FDCA”).29  In accordance with this authority, the FDA created 
its three-phase drug approval process,30 which state Right to Try 
laws attempt to circumvent.31  It is not possible to comply with 
both state Right to Try laws and federal regulatory requirements 
simultaneously.32  Thus, although the FDCA does not contain any 
express preemption provision,33 such state laws, which upset the 
congressional purpose set forth in the FDCA,34 would likely be 
preempted.35 
For state Right to Try laws to escape federal preemption, 
federal action is necessary.  Although the FDA has its own 
Expanded Access program to address the needs of terminally ill 
patients,36 the FDA does not support Right to Try laws.37  In a 
 
28 U.S. CONST. art. VI, cl. 2. 
29 Food, Drug, and Cosmetic Act, 21 U.S.C. § 301 (2012). 
30 Id. § 355(D)(i)(II); see also Martin, supra note 27, at 168. 
31 Emily Hogan, Note, “Right to Try” Legislation and Its Implications for the 
FDA Drug Approval Process, 50 WASH. U. J.L. & POL’Y 171, 186–87 (2016). 
32 21 U.S.C. § 355(a) (2012); see also Martin, supra note 27, at 163 (“A ‘direct 
conflict’ exists between the FDCA and state Right to Try laws because it is 
impossible for organizations to comply with both laws, and the purpose of the FDA 
to regulate new drugs is undoubtedly frustrated.”). 
33 21 U.S.C. § 301 (2012). 
34 United States v. Article of Drug Bacto-Unidisk, 394 U.S. 784, 798 (1969) 
(“[T]he Act’s overriding purpose [is] to protect the public health, and specifically, 
§ 507’s purpose [is] to ensure that [drugs] marketed serve the public with ‘efficacy’ 
and ‘safety.’ “) (first citing United States v. Sullivan, 332 U.S. 689, 693–95 (1948); 
and then citing United States v. Dotterweich, 320 U.S. 277, 283–84 (1943)). 
35 Jonathan J. Darrow et al., Practical, Legal, and Ethical Issues in Expanded 
Access to Investigational Drugs, 372 NEW ENG. J. MED. 279, 283 (2015). “[R]ight-to-
try laws are unlikely to withstand a constitutionality challenge that is based on 
conflict with the FDA’s enabling legislation and existing expanded-access 
regulations.” Id. 
36 21 C.F.R. § 312 (2016); see also Expanded Access (Compassionate Use), U.S. 
FOOD & DRUG ADMIN., http://www.fda.gov/NewsEvents/PublicHealthFocus/Expand 
edAccessCompassionateUse/default.htm (last updated Oct. 3, 2017). Unfortunately, 
Right to Try law advocates do not believe that the FDA’s expanded access program is 
speedy enough nor that it helps enough people. See, e.g., Bellina, supra note 21 
(describing the FDA’s compassionate use program as “severely flawed”). 
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September 2016 statement, Peter Lurie, the FDA’s Associate 
Commissioner for Public Health and Analysis, stated that 
“[c]linical trials remain the best option for patients wishing to 
gain access to investigational products and . . . the approval 
process remains the best way to assure the development of and 
access to safe and effective new medical products for all 
patients.”38 
Although there is no fundamental right to try, and state 
Right to Try laws are likely federally preempted, a congressional 
statute would transcend both obstacles.39  However, right to try 
opponents, and their valid concerns, complicate the passage of 
such a statute.40  Two opposing arguments are particularly 
powerful. 
First, if experimental drugs become more readily available 
outside of clinical trials, it becomes increasingly difficult to 
maintain the numbers necessary to perform these trials, which 
harms the public health at large.41  Phase-three trials require 
anywhere from three-hundred to three-thousand participants 
suffering from the disease or condition.42  Relatively few patients 
enroll in trials as is.43  The three-phase clinical-trial system is 
 
37 Exploring a Right to Try for Terminally Ill Patients: Hearing on S. 2912 
Before the S. Comm. On Homeland Sec. and Gov’t Aff., 114th Cong. 5 (2016) 
[hereinafter Senate Hearing] (statement of Peter Lurie, Associate Commissioner for 
Public Health Strategy and Analysis, U.S. FDA). 
38 Id. 
39 James M. Beck, Developments in Compassionate Use and Right to Try Laws, 
DRUG & DEVICE LAW (June 9, 2016), https://www.druganddevicelawblog.com/2016 
/06/developments-in-compassionate-use-and-right-to-try-laws.html (explaining that 
state Right to Try laws would no longer be preempted if a federal Right to Try law 
was adopted.). 
40 For example, Senator Ron Johnson, the Trickett Wendler Act’s sponsor, 
recently went to the Senate floor to seek unanimous consent for the bill, but was 
blocked by Senate Minority Leader Harry Reid, an opponent of Right to Try laws. 
Johnson Fails in Bid To Hotline ‘Right to Try’ Bill Through Senate, INSIDE HEALTH 
POLICY (Sept. 28, 2016), https://insidehealthpolicy.com/daily-news/johnson-fails-bid-
hotline-right-try-bill-through-senate. See also supra note 12 
41 VICTORIA WEISFELD ET AL., PUBLIC ENGAGEMENT AND CLINICAL TRIALS: NEW 
MODELS AND DISRUPTIVE TECHNOLOGIES 2 (2012) (identifying “the increasing 
difficulty of recruiting and retaining an appropriate human subject population for 
specific clinical trials” as a “significant problem”); see also Manik Chahal, Off-Trial 
Access to Experimental Cancer Agents for the Terminally Ill: Balancing the Needs of 
Individuals and Society, 36 J. MED. ETHICS 367, 368 (2010). 
42 The Drug Development Process, Step 3: Clinical Research, U.S. FOOD & DRUG 
ADMIN., http://www.fda.gov/ForPatients/Approvals/Drugs/ucm405622.htm#Clinical_ 
Research_Phase_Studies (last updated May 25, 2017). 
43 WEISFELD ET AL., supra note 41, at 2. 
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essential to determining whether experimental drugs are 
sufficiently safe and effective for consumption by the general 
patient population.44  Thus, if trials cannot recruit patient 
volunteers, then an already lengthy process loses all efficacy and 
speed, and in turn cannot serve the public as intended.45 
Second, early access to a drug may cause a person more 
harm than good.46  Right to Try laws grant access to 
investigational drugs that have passed the first of three phases of 
FDA clinical trials.47  Unfortunately, Phase One trials are small, 
usually conducted on about twenty to a hundred human subjects, 
and are not designed to evaluate effectiveness; the purpose is 
simply to supply initial information about the drug’s adverse 
effects on humans.48  About seventy percent of drugs move on to 
the second phase, which provides researchers with additional 
safety data.49  Although Phase Two studies are conducted on 
several hundred people, they are still not considered large 
enough to demonstrate whether the drug will be beneficial, as 
evidenced by the fact that two more phases are conducted on up 
to several thousand subjects.50  The determination of how 
beneficial a drug is, is made during phase-three studies, which 
demonstrate whether or not a product offers a treatment benefit 
to a specific population.51 
 
 
44 See 21 U.S.C.A. § 355(d) (West 2014) (requiring clinical investigations of the 
safety and efficiency of a drug prior to FDA approval). 
45 Senate Hearing, supra note 37 (statement of Peter Lurie, Associate 
Commissioner for Public Health Strategy and Analysis, U.S. FDA) (“Enrollment in 
clinical trials helps to ensure adequate protection for patients and leads to the 
collection of vital data that could eventually result in FDA approval of the 
investigational product.”). 
46 David Gorski, The False Hope of “Right-to-Try” Metastasizes to Michigan, 
SCI.-BASED MED. (July 21, 2014), https://www.sciencebasedmedicine.org/the-false-
hope-of-right-to-try-metastasizes-to-michigan/ (explaining that disaster can result 
when compassion gets in the way of medical decision making). 
47 See COLO. REV. STAT. § 25-45-103(2) (2014) (an experimental drug is one “that 
has successfully completed phase one of a clinical trial but has not yet been approved 
for general use by the [FDA]”). 
48 The Drug Development Process, Step 3: Clinical Research, supra note 42. 
49 Id. 
50 Id. 
51 Id. (“Phase 3 studies provide most of the safety data. In previous studies, it is 
possible that less common side effects might have gone undetected. Because these 
studies are larger and longer in duration, the results are more likely to show long-
term or rare side effects[.]”). 
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Yet, terminal patients and their advocates remain eager to 
access unapproved “miracle drugs,” believing they will save lives 
if only patients could get their hands on them.52  Patients and 
their advocates are thus ignoring the suffering that can come 
from trying novel drugs.  But, if a patient is terminal, what is the 
harm in trying?  One expert responds, “If there’s anything worse 
than dying of a terminal illness, it’s dying of a terminal illness 
and suffering unnecessary complications or pain for no 
benefit[.]”53  Even patients with life-threatening diseases require 
protections from unnecessary risks.54  For a federal Right to Try 
law to be successful, it must address these concerns. 
II. COMPARING RIGHT TO TRY LAWS 
State “Right to Try” laws are new, controversial, and, most 
problematically, different from one another.  Inviting states with 
varying views on the right to try to fill in Congress’s blanks 
muddles the already shaky definition of a “right to try.”  This 
Part highlights several critical differences between Right to Try 
laws that, without well-defined congressional intervention, will 
remain problematic. 
A. Eligibility Requirements 
All “Right to Try” laws include a list of criteria that a patient 
must meet to become an “eligible patient” for right to try 
purposes.55  Generally, a state’s eligibility list is comprised of 
some combination of five conditions: (1) The patient has a 
terminal illness, attested to by his or her physician; (2) The 
patient has considered all other treatment options currently 
 
52 David Gorski, “Right to Try” Laws and Dallas Buyers’ Club: Great Movie, 
Terrible for Patients and Terrible Policy, SCI.-BASED MED. (Mar. 8, 2014), 
https://www.sciencebasedmedicine.org/right-to-try-laws-and-dallas-buyers-club-grea 
t-movie-terrible-public-policy/ (alluding to the “misperception that there are ‘miracle 
drugs’ out there that we will have to wait years for because the FDA is too slow to 
approve them”); see also Julie Brintnall-Karabelas et al., Improving Recruitment in 
Clinical Trials: Why Eligible Participants Decline, 6 J. EMPIRICAL RES. ON HUM. 
RES. ETHICS 69, 70 (2011). 
53 Gorski, supra note 52. 
54 Senate Hearing, supra note 37 (statement of Peter Lurie, Associate 
Commissioner for Public Health Strategy and Analysis, U.S. FDA). 
55 Right to Try Model Legislation, GOLDWATER INST., § 1(2)(b), https://goldwater-
media.s3.amazonaws.com/cms_page_media/2015/1/28/RIGHT%20TO%20TRY%20M
ODEL%20LEGISLATION%20%282%29_1.pdf (last visited Dec. 27, 2017); see also 
POLICY SURVEILLANCE PROGRAM STAFF, RIGHT TO TRY LAWS 1 (Oct. 2016). 
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approved by the FDA; (3) The patient has received a 
recommendation from his or her physician for the investigational 
treatment sought; (4) The patient has given written, informed 
consent for the use of the investigational treatment; and (5) The 
patient has documentation from his or her physician that he or 
she meets all of the eligibility requirements.56 
Two of these requirements have been adopted by all states 
with Right to Try laws.  The first is requirement number two, 
that the patient has considered all other currently approved 
treatment options.57  This is also a necessary requirement to be 
eligible for the FDA’s Expanded Access program.58  This 
requirement aligns with the very important policy interest that 
the unapproved drug be a last resort option.  If a patient can 
receive the treatment he or she needs without having to shoulder 
the potential risks of an unapproved drug, Right to Try laws need 
not and should not be utilized. 
The second widely adopted requirement is number four, that 
the patient provide “written, informed consent for the use of the” 
experimental treatment.59  A majority of states additionally 
define “written, informed consent,” specifying information that 
must be included in the informed consent document.60  The FDA’s 
Expanded Access program also requires written, informed 
 
56 Right to Try Model Legislation, supra note 55. The Goldwater Institute is a 
pubic policy think tank that has outlined proposed Right to Try legislation. Michelle 
J. Rubin & Kristin R.W. Matthews, The Impact of Right to Try Laws on Medical 
Access in the United States, 66 BAKER INST. POL’Y REP. 1, 6 (2016). State Right to 
Try laws are generally similar to the Goldwater Institute’s template. Id. 
57 Right to Try Model Legislation, supra note 55, § 1(2)(b)(ii). 
58 21 C.F.R. § 312.305(a)(1) (2016). 
59 Right to Try Model Legislation, supra note 55, § 1(2)(b)(iv). 
60 E.g., COLO. REV. STAT. § 25-45-103(4) (2014) (stating that “written, informed 
consent” documents must, at the very least, (a) “explain[] the currently approved 
products and treatments for the disease or condition from which the patient suffers;” 
(b) “attest[] to the fact that the patient concurs with his or her physician” that all 
currently approved treatments are inadequate; (c) define[] the specific experimental 
drug; (d) “describe[] the potentially best and worst outcomes of using the 
[experimental] drug . . . including the possibility that new, unanticipated, different, 
or worse symptoms might result” and could precipitate death; (e) “[m]ake[] clear that 
the patient’s health insurer and provider are not obligated to pay for any care or 
treatments consequent to the use of the [experimental] drug”; (f) clearly state that 
the patient may no longer be eligible for hospice care; (g) clearly state that the 
patient may be denied in-home healthcare because of the treatment; and (h) “state[] 
that the patient understands that he or she is liable for all expenses consequent to 
the use of the [experimental] drug . . . unless a contract between the patient and the 
manufacturer of the drug . . . states otherwise.”). 
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consent and provides for what information must be included in 
that document.61  This requirement reflects the state’s interest in 
protecting the patient.  Opponents’ concern that a desperate 
patient may be lured by the idea of a miracle drug is softened 
when that patient is provided with enough information to make 
an informed, autonomous decision.  While a patient may still 
hope for a miracle, a comprehensive informed consent document 
emphasizes that the drug remains unapproved, and, thus, its 
outcome cannot be predicted and worse symptoms might result. 
While these two requirements evoke widespread acceptance, 
the first and arguably most basic requirement, that the patient 
be terminally ill, lacks any single accepted definition.62  State 
Right to Try laws tend to define a “terminally ill” patient in one 
of three ways: (1) He or she has a disease or condition not 
considered to be reversible, even with the administration of 
currently approved and available treatment options; (2) He or 
she has a disease or condition that, in running its normal course, 
will end his or her life within a certain period of time; or (3) He or 
she has a disease or condition likely to result in death or is in a 
permanent state of unconsciousness from which recovery is 
unlikely.63 
At least seven states have taken the first approach.64  This 
approach generally defines a terminal illness as “[a] progressive 
disease or medical or surgical condition that (i) entails significant 
functional impairment, (ii) is not considered by a treating 
physician to be reversible even with administration of available  
 
 
61 21 C.F.R. § 50.25(a) (2016).  
62 See United States v. Rutherford, 442 U.S. 544, 556 (1979) (noting the 
difficulties of defining terminally ill and applying that definition to patients); see 
also Joanne Lynne et al., Defining the “Terminally Ill:” Insights from Support, 35 
DUQ. L. REV. 311, 311–12 (1996). 
63 Victoria Howard, Note, Accessing Indiana’s Right-to-Try Law: Is It Enough To 
Expand Access for Terminally Ill Patients?, 14 IND. HEALTH L. REV. 267, 292–99 
(2017). Only one state, Indiana, does not require that the patient’s disease or 
condition be life-threatening. IND. CODE ANN. § 25-22.5-1-2.1 (West 2015) (stating 
that an individual may access an experimental drug if he or she has been diagnosed 
with a terminal condition or if the patient’s treating physician determines that 
“there is no reasonable basis to conclude” that the experimental drug, when 
administered appropriately, “poses an unreasonable and significant risk” to the 
patient).  
64 Alabama, Michigan, Minnesota, Montana, North Carolina, South Dakota, and 
Tennessee. 
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treatments approved by the [FDA], and (iii) will soon result in 
death without life-sustaining procedures.”65  This definition is 
comprised of several important components. 
First, it requires that the patient’s condition causes or 
involves “significant functional impairment.”  No state explicitly 
defines “significant functional impairment.”66  The sixth edition 
of the American Medical Association’s Guides to the Evaluation of 
Permanent Impairment, defines impairment as “a significant 
deviation, loss, or loss of use of any body structure or function in 
an individual with a health condition, disorder, or disease.”67  The 
Social Security Administration defined a medically determinable 
impairment as “an impairment that results from anatomical, 
physiological, or psychological abnormalities that can be shown 
by medically acceptable clinical and laboratory diagnostic 
techniques.”68  Thus, there is no explicit determinable factor of a 
“significant functional impairment.”  Minnesota, one of the nine 
states adopting this approach, deleted this distinction from its 
definition, asserting simply that a terminal disease or condition 
is one “not considered reversible” and that “will soon result in 
death.”69 
Despite the lack of clarity as to what exactly constitutes a 
“significant functional impairment,” or if such characteristic is 
necessary, it is clear that the legislators intended for the 
patient’s condition to be significant enough to warrant the 
extraordinary permission being granted.  This cautions against 
unjustified determination of an eligible “terminally ill” patient 
and reinforces the idea of the right to try as a last resort. 
Second, this approach requires that the disease or condition 
not be reversible by current FDA approved treatments.70  Once 
again, this is consistent with the intent that the law be used only 
as a last resort.  If a patient’s condition can be treated through 
an approved option, experimenting with an unapproved drug 
outside of a clinical trial is unwarrantedly risky. 
 
65 E.g., N.C. GEN. STAT. § 90-325.1(3) (2015). 
66 See id. 
67 ROBERT D. RONDINELLI ET AL., GUIDES TO THE EVALUATION OF PERMANENT 
IMPAIRMENT, 876 (6th ed. 2008). 
68 Disability Evaluation Under Social Security: Part I—General Information, 
SOC. SEC. ADMIN., https://www.ssa.gov/disability/professionals/bluebook/general-info 
.htm (last visited Dec. 27, 2017). 
69 MINN. STAT. § 151.375(2)(d) (2015). 
70 See supra note 64. 
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Third, this approach requires that the patient’s disease or 
condition “will soon result in death.”71  This requirement goes to 
the heart of what a terminal illness realistically is—an illness 
that will take a patient’s life—and illustrates why Right to Try 
laws are necessary; without them, the patient will die.  The 
keyword in this first approach is “soon.” 
This differs from the second approach, embraced by four 
states,72 which demarcates a particular period of time in which 
death must be likely to occur.  For example, Florida defines a 
terminal illness as a condition that, in running its normal course, 
will result in death “within 1 year after diagnosis.”73  Oregon 
defines it as a disease or condition that, in the “physician’s 
reasonable medical judgment,” will result in death within six 
months.74 
Conversely, at least nine states do not draw a definitive line 
for the time period within which death must occur, simply 
requiring that death be projected to occur soon,75 in the near 
future,76 or imminently.77 
Regardless of which method a state adopts, this provision 
reinforces the objective that Right to Try laws be utilized only as 
a last resort.  While states like Florida and Oregon are stricter in 
their definition of “terminally ill,” the other thirteen states that 
do not demarcate a “death-by-date” allow more room for 
interpretation.  Still, the point remains clear—the right to try 
only becomes a “right” when accompanied by a patient’s 
foreseeable demise. 
 
 
71 Right to Try Model Legislation, supra note 55, § 1(2)(a). 
72 Florida, Nevada, Illinois, and Oregon. 
73 FLA. STAT. ANN. § 499.025(2)(c) (West 2015). 
74 H.R. 2300 § 1(9), 78th Leg. Assemb., Reg. Sess. (Or. 2015). 
75 Alabama, Colorado, Maine, Michigan, Minnesota, Montana, North Carolina, 
Wyoming, and Oklahoma. See e.g., COLO. REV. STAT. § 25-45-103(3) (2014) 
(“ ‘Terminal Illness’ means a disease that, without life-sustaining procedures, will 
soon result in death . . . .”). 
76 Mississippi, Missouri, and Vermont. E.g., MISS. CODE ANN. § 41-131-1(2)(c) 
(West 2016) (“ ‘Terminal illness’ means a disease that without life-sustaining 
procedures will result in death in the near future . . . .”). 
77 VA. CODE ANN. § 54.1-3442.1 (West 2015) (“ ‘Terminal condition’ means a 
condition caused by an injury, disease, or illness, from which . . . the patient’s death 
is imminent . . . .”). 
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The third approach, adopted by at least seven states,78 
includes as “terminal illness” not only parties with death-
triggering diseases, but also patients in “a state of permanent 
unconsciousness from which recovery is unlikely.”79  By 
expanding their definition, these states include patients who may 
ordinarily not be categorized as “terminally ill,”80 but have 
similarly hopeless prognoses.81 
Unfortunately, having three different definitions of 
“terminally ill” will ultimately result in numerous bioethical 
issues for patients and physicians.82  For example, different 
definitions cause similar patients across the country to receive 
different levels of access to experimental drugs.83  Additionally, 
physicians and patients, or physicians and patients’ family 
members, might disagree over whether or not a patient is eligible 
for the right to try, which might result in litigation.84 
To supplement the five typical eligibility requirements, some 
states have adopted their own additional eligibility requirements.  
Two noteworthy requirements are (1) The patient is “unable to 
participate in a clinical trial;”85 and (2) The potential risks of 
using the experimental drug do not outweigh the potential 
benefits. 
 
78 Colorado, Maine, Mississippi, Missouri, North Dakota, Oklahoma, and 
Wyoming. 
79 COLO. REV. STAT. § 25-45-103(3) (2014). 
80 See Sally J.T. Necheles, Particular Medical Conditions for Which Withdrawal 
of Treatment May Be Available, 77 C.J.S. RIGHT TO DIE § 18 (2017); see also Health 
Maintenance Guidelines Terminology, PALO ALTO MED. FOUND., 
http://www.pamf.org/preventive/AHCD-terminology.html (last visited Dec. 27, 2017) 
(stating that a “[p]ersistent vegetative state” is “[n]ot normally regarded as a 
terminal condition and the patient can survive for many years with medical care, 
artificial fluids and nutrition”). 
81 The Multi-Society Task Force on PVS, Medical Aspects of the Persistent 
Vegetative State, 330 NEW ENG. J. MED. 1572, 1575–76 (1994) (explaining that 
survival rates for patients in a persistent vegetative state is extremely low). 
82 See Diane E. Hoffman & Anita J. Tarzian, The Role and Legal Status of 
Health Care Ethics Committees in the United States, in LEGAL PERSPECTIVES IN 
BIOETHICS 52 (Ana S. Iltis et al. eds., Taylor & Francis e-Library ed. 2007) 
(explaining how states’ differing definitions of terminal illness present bioethical 
problems). 
83 Richard M. Doerflinger, Conclusion: Shaky Foundations and Slippery Slopes, 
35 DUQ. L. REV. 523, 525 (1996) (stating that an arbitrary definition of “terminal 
illness” raises prompt “ ‘equal protection’ claims by patients who fall just outside the 
definition’s borders”). 
84 See Hoffman & Tarzian, supra note 82, at 54 (explaining that physicians and 
family members might have differing views on a patient’s medical prognosis). 
85 OKLA. STAT. ANN. tit. 63, § 3091.2(1)(c) (West 2015). 
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According to the first, a patient is only an “eligible patient” 
for purposes of the law if he or she is unable to participate in a 
clinical trial for the requested experimental treatment.  
Oklahoma, for example, requires that the patient either be 
“unable to participate in a clinical trial for the terminal illness 
within one hundred . . . miles of the patient’s home address, or 
not been accepted to the clinical trial within one . . . week of the 
completion of the clinical trial application process[.]”86  By 
requiring that patients first attempt to access the drug through 
the clinical trial process, these additional requirements mitigate 
the concern that trials will suffer if Right to Try laws are 
legalized.87  Oklahoma’s distance limitation remains 
compassionate to terminally ill patients that are unable to travel 
far distances from their homes or hospitals.88  Oklahoma’s timing 
limitation recognizes that many terminally ill patients do not 
have the time to wait for an acceptance to a clinical trial.89 
The second additional requirement, adopted by three 
states,90 requires a physician to ascertain that the experimental 
drug’s potential risks to the patient do not outweigh its potential 
benefits to the patient.91  The FDA’s expanded access program 
similarly requires a determination by the FDA that the “patient 
benefit justifies the potential risks of the treatment use and [the] 
potential risks are not unreasonable in the context of the 
disease . . . .”92 
Such risk-benefit analyses compel physicians to look at their 
patients’ situations analytically and objectively, allowing the 
physician to make a more informed, and ideally less emotional, 
decision for his or her patient.  Although the risks and benefits of 
 
86 Id. Maine includes a similar provision, stating that an “eligible patient” is one 
who has “[n]ot been accepted into a clinical trial within one week of completion of 
the clinical trial application process[.]” ME. STAT. tit. 602-A, § 2671(1)(c) (2016). 
87 See WEISFELD, supra note 41 and accompanying text for an explanation of the 
argument that clinical trials might suffer as a result of Right to Try legislation. 
88 CORIERI, supra note 17, at 11 (stating that many patients “do not live near or 
have the ability to travel to a medical facility where [a clinical] trial is being 
conducted”). 
89 See id. 
90 Indiana, Virginia, and Utah. 
91 See VA. CODE ANN. § 54.1-3442.2(A)(3) (West 2015) (“The potential benefits of 
use of the investigational drug . . . are greater than the potential risks of the use of 
the investigational drug . . . .”). 
92 FDA Expanded Access to Investigational Drugs, 21 C.F.R. § 312.305(a)(2) 
(2016). 
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a potential drug to a particular patient are largely 
undeterminable at this state, “the physician should make this 
determination based on the information about the drug available 
to the physician and the physician’s knowledge of the patient’s 
clinical situation.”93  This analysis thus ensures that the current 
foreseeable risks are no greater than the current foreseeable 
benefits, in the patient’s particular circumstance.  The patient 
should be made aware that they may suffer unanticipated risks, 
and that foreseeable benefits are not guaranteed, in his or her 
informed consent document. 
B. Manufacturer Protections 
All Right to Try laws share one important aspect: it is 
entirely the drug manufacturer’s decision whether to make its 
investigational drug available to an eligible patient.94  If the 
manufacturer, having ultimate control over the drug, chooses not 
to participate in the “right to try” process, then the law cannot 
achieve its purpose. 
Manufacturers are “rational economic actor[s],” whose 
purpose is to get their drugs on the market.95  Thus, factors such 
as the threat of liability and the FDA’s approval process will 
likely deter any voluntary action by a manufacturer.96  Because 
Right to Try laws cannot succeed without manufacturer 
participation, some states have included provisions to protect 
manufacturers from liability and the FDA’s approval process.  
The FDA’s Expanded Access program offers no such protections 
for manufacturers. 
Nineteen states have adopted provisions protecting 
manufacturers from liability.97  Generally, such provisions 
provide that there is no private cause of action created against a 
 
93 FOOD & DRUG ADMIN., EXPANDED ACCESS TO INVESTIGATIONAL DRUGS FOR 
TREATMENT AND USE—QUESTIONS AND ANSWERS 11 (Oct. 2017), https://www. 
fda.gov/downloads/drugs/guidances/ucm351261.pdf. 
94 James M. Beck, On “Right to Try” Legislation, DRUG & DEVICE LAW (Oct. 23, 
2014), https://www.druganddevicelawblog.com/2014/10/on-right-to-try-legislation.ht 
ml. 
95 Id. 
96 Id. (“You won’t induce a manufacturer to participate in a voluntary program 
by painting a target on its back.”). 
97 Alabama, Arizona, Colorado, Florida, Indiana, Maine, Michigan, Minnesota, 
Mississippi, Montana, Nevada, North Carolina, North Dakota, Oklahoma, South 
Dakota, Texas, Virginia, and Wyoming. 
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manufacturer, or any other person or entity involved in the care 
of an eligible patient using an investigational drug, if the 
manufacturer or other person or entity is complying with the 
statute in good faith and with reasonable care.98 
Two states, Indiana and Texas, have adopted slightly edited 
versions of this provision, which may ultimately have destructive 
effects.99  Both states’ laws provide that there is no cause of 
action against a manufacturer, but neither requires that the 
manufacturer act in good faith or with reasonable care to invoke 
the protection.  Critics have expressed concern, echoed by the 
FDA, that unregulated manufacturers might take advantage of 
desperate patients.100 
Umbrella protection generates concern that less scrupulous 
manufacturers may negligently, or even willfully, provide a 
desperate patient with an unsafe drug.  A manufacturer who 
knows, or reasonably should know, that its drug is unsafe for 
human consumption, may be less prudent when distributing the 
drug if it cannot be held liable. 
Additionally, a majority of Right to Try laws allow 
manufacturers to decide whether and what to charge a patient 
for its drug.101  Under all Right to Try laws, a patient’s health 
insurance provider is not required to cover costs associated with 
an experimental drug.102  Thus, patients may be left with costly 
medical bills.  Concern follows that “without proper oversight” a 
manufacturer could “inflate the cost associated with the 
production of the drug and take advantage of” a distressed and  
 
 
98 See, e.g., COLO. REV. STAT. § 25-45-107 (2014). 
99 IND. CODE ANN. § 16-42-26-5 (West 2015); TEX. HEALTH AND SAFETY CODE 
ANN. § 489.054 (West 2015). 
100 Senate Hearing, supra note 37 (statement of Peter Lurie, Associate 
Commissioner for Public Health Strategy and Analysis, U.S. FDA) (“FDA is 
concerned about the ability of unscrupulous individuals to exploit such desperate 
patients.”); see also Jonathan Friedlaender, The Proposed Federal “Right-To-Try” 
Law is Not the Answer for Critically Ill Patients, HEALTH AFFAIRS (Sept. 27, 2016), 
http://www.healthaffairs.org/do/10.1377/hblog20160927.056819/full (“Without safe-
guards, less scrupulous providers will take advantage.”). 
101 See, e.g., MINN. STAT. § 151.375(5) (2015). 
102 See, e.g., id. § 151.375(7). 
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desperate class of people.103  Umbrella protection for 
manufacturers, with no requirement that they act with good 
faith or reasonable care, makes this concern more realistic. 
Some states have taken steps to mitigate this concern.  
Arizona, for example, allows a manufacturer to charge only the 
out-of-pocket costs expended in providing that particular drug to 
that particular patient.104  This is also the approach taken by the 
FDA’s Expanded Access program.105  Other states, such as Texas, 
prohibit the manufacturer from charging at all.106 
In states that do not specify what the manufacturer may 
charge, an equality discussion has transpired.  If a patient bears 
the total cost of an experimental drug, and there is no cap on the 
cost, this law in effect is a law for the wealthy.107  The “right” in 
right to try is the right to fight to save your life, but that right 
would only be available for those who can afford it.108  South 
Dakota allows a manufacturer to use its discretion to provide a 
drug to an eligible patient without compensation.109  Requiring a 
manufacturer to provide a drug removes any financial incentive 
for the manufacturer to participate in “right to try”; laws such as 
South Dakota’s at least encourage a manufacturer to act when an 
eligible patient is unable to afford the drug. 
The second factor important in encouraging manufacturers’ 
voluntary participation is to prohibit the use of adverse events 
suffered by right to try patients in the drug’s FDA approval 
process.110  Typically, a drug manufacturer’s end goal is to 
market its drug to the public.  If negative side effects suffered by 
a single patient, outside the scope of mandatory clinical trials, 
deter achievement of that goal, a manufacturer is less likely to 
 
103 Jessica M. Maxwell, Patients’ Right to Choose; The Right-To-Try Law 
Movement, 9 HEALTH L. OUTLOOK 1, 4 (2016), http://scholarship.shu.edu/health-law-
outlook/vol9/iss1/5. 
104 ARIZ. REV. STAT. ANN. § 36-1312(B)(1)–(2) (2014). 
105 FOOD & DRUG ADMIN., CHARGING FOR INVESTIGATIONAL DRUGS UNDER AN 
IND—QUESTIONS AND ANSWERS 7–8 (June 2016), https://www.fda.gov/downloads/ 
drugs/guidancecomplianceregulatoryinformation/guidances/ucm351264.pdf. 
106 TEX. HEALTH AND SAFETY CODE. ANN. § 489.053(c) (2015). 
107 Y. Tony Yang et al., “Right-To-Try” Legislation: Progress or Peril?, 33 J. 
CLINICAL ONCOLOGY 2597, 2598 (2015) (explaining the issue of “access disparities 
because only the wealthy would be able to access” experimental treatments). 
108 Id.; see also Joel B. Finkelstein, FDA Clarifies Rules for Getting Experimental 
Drugs, 99 J. NAT’L CANCER INST. 584, 585 (2007). 
109 H.B. 1080, 90th Leg. Assemb. Sess. (S.D. 2015). 
110 Beck, supra note 39. 
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voluntarily provide its drug to that patient.  While no state Right 
to Try law has addressed whether or not a manufacturer must 
report adverse events suffered by a patient to the FDA, the 
Trickett Wendler Act prevents the FDA from using such side 
effects to adversely impact review or approval of the drug.111  
Conversely, the FDA’s Expanded Access program requires that 
any side effects be reported as part of the drug’s approval 
process.112 
The FDA has an interest in protecting the public health at 
large.  If not properly addressed, a negative side effect suffered 
by one person could become a negative side effect suffered by 
another.113  Thus, while a manufacturer’s voluntary participation 
is necessary for a successful Right to Try statute, it remains 
critical that the FDA account for all possible side effects of a drug 
in that drug’s approval process.114  Further, there may be other 
ways to incentivize manufacturer participation without 
disrupting our system, such as by offering tax breaks or federal 
subsidies for manufacturers that comply;115 or, better yet, 
requiring manufacturers to report adverse side effects while 
barring the FDA from rejecting a drug on the basis of reports 
from terminally ill patients. 
C. Similarities Between Right To Try Laws 
While Right to Try laws are permeated with differences, they 
also share two notable similarities: (1) the definition of 
“experimental drug,” and (2) physical protection. 
 
111 S. 2912, 114th Cong. § 2(b)(2) (2016) (“[T]he outcome of any production, 
manufacture, distribution, prescribing, dispensing, possession, or use of” such a 
treatment “shall not be used by a Federal agency . . . [to] adversely impact review or 
approval of [the treatment].”). 
112 21 C.F.R. § 312.305(4)–(5) (2016). The FDA has a responsibility to protect the 
public health. Therefore, the FDA has a substantial interest in gathering all 
information about the effects of a drug in order to safely make that drug available 
for the public. Senate Hearing, supra note 37 (statement of Peter Lurie, Associate 
Commissioner for Public Health Strategy and Analysis, U.S. FDA). 
113 How FDA Evaluates Regulated Products: Drugs, U.S. FOOD & DRUG ADMIN., 
http://www.fda.gov/AboutFDA/Transparency/Basics/ucm269834.htm (last updated 
Nov. 16, 2017). 
114 Id. 
115 Rubin & Matthews, supra note 56, at 11 (“Congress and the FDA can 
incentivize manufacturers’ participation in expanded access by offering tax breaks if 
the company participates.”). 
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First, all Right to Try laws have the same definition for 
“experimental drug.”  An experimental drug is “a drug, biological 
product, or device that has successfully completed phase one of a 
clinical trial but has not yet been approved for general use by the 
United States food and drug administration and remains under 
investigation in a United States food and drug administration-
approved clinical trial.”116 
Despite the definition’s wide adoption by state Right to Try 
laws, the Trickett Wendler Act, and even the FDA Expanded 
Access program, substantial debate remains over whether Phase 
One drugs are safe enough for Right to Try purposes.117  By their 
definition, Phase One drugs are not considered safe and 
effective.118  Phase One trials are conducted on only about twenty 
to eighty participants with the purpose of gathering preliminary 
information about the drug’s dosage and acute side effects.119  
Most of the drug’s safety data is not gathered until Phase Three 
studies, which are conducted on hundreds, sometimes thousands, 
of patients.120  Additionally, about eighty-six percent of drugs 
that move beyond Phase One “prove to be less effective than” 
drugs already on the market.121  Nonetheless, legislators have 
accepted Phase One as the threshold for Right to Try laws 
nationwide. 
 
 
 
116 See, e.g., COLO. REV. STAT. § 25-45-103(2) (2014). 
117 See ‘Right to Try’ Laws Make Safety, Efficacy Secondary to Speedy Access, 
SCIENCEDAILY (May 19, 2016), https://www.sciencedaily.com/releases/2016/05/1605 
19121110.htm (arguing that Right to Try laws make safety secondary to speedy 
access); see also Finkelstein, supra note 108 (arguing that asking for access to 
experimental drugs is like “asking the government to sanction the sale of toxic 
placebos . . . to say those should be sold to [terminal patients] is just irresponsible”). 
But see Frequently Asked Questions, RIGHT TO TRY, http://righttotry.org/faq/ (last 
visited Dec. 27, 2017) (arguing that experimental drugs that have passed Phase One 
testing are no different than the treatments currently available to patients who are 
lucky enough to be accepted into clinical trials). 
118 See The Drug Development Process, Step 3: Clinical Research, supra note 42 
(FDA explains its three-phase approval process). 
119 Id. 
120 Id. (pre-phase three studies might not have detected less common side 
effects). 
121 Jeff Schriber et al., Doctors: Prop. 303 Isn’t in Patients’ Best Interests, ARIZ. 
REPUBLIC (Oct. 14, 2014, 3:20 PM), https://www.azcentral.com/story/opinion/op-ed/2 
014/10/14/no-prop-303-right-to-try/17270791/. 
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At their core, Right to Try laws are intended to serve the 
terminally ill.  It is estimated that the entire drug approval 
process, on average, takes between eight to twelve years.122  
Terminally ill patients, therefore, may die while waiting for a 
drug to come to market or to pass on to a higher phase.123  
Terminal patients are often ineligible from participating in a 
clinical trial for a variety of reasons, such as age, gender, medical 
history, or current medical status.124  With death imminent, 
patient advocates argue that risky but potentially beneficial 
treatment is better than inaction.125 
Second, all Right to Try laws offer some form of protection 
for physicians who prescribe, advise, dispense, administer, or are 
otherwise involved in the care of an eligible patient using an 
experimental drug.126  No law requires that a physician partake 
in the process; that decision is solely within the discretion of the 
physician.127  However, if a physician chooses to participate and 
acts with reasonable care, he or she is protected from liability 
and his or her medical license is protected from any form of 
reprimand.128  This is an important feature of Right to Try laws 
because it allows physicians to act in the best interest of their 
patients without fear of being penalized.  It also encourages 
voluntary participation from physicians. 
III. A MODEL CONGRESSIONAL RIGHT TO TRY STATUTE 
Despite the inconsistencies among state Right to Try laws, 
the Trickett Wendler Act is a meager six sentences.129  While 
there is power behind those six sentences, there is not enough 
clarity.  The Trickett Wendler Act is extremely deferential to 
state Right to Try laws in areas where there is no consensus.130  
 
122 Martin S. Lipsky & Lisa K. Sharp, From Idea to Market: The Drug Approval 
Process, 14 J. AM. BOARD FAM. MED. 362, 364 (2001). 
123 Rubin & Matthews, supra note 56, at 4. 
124 Roswell Park Cancer Institute, What Are Eligibility Criteria, and Why Are 
They Important?, https://www.roswellpark.org/clinical-trials/eligibility-criteria (last 
visited Dec. 27, 2017). 
125 Julie Turkewitz, Patients Seek ‘Right to Try’ New Drugs, N.Y. TIMES (Jan. 10, 
2015), http://www.nytimes.com/2015/01/11/us/patients-seek-right-to-try-new-drugs. 
html. 
126 E.g., ALA. CODE §§ 22-5D-6, 22-5D-10 (2015). 
127 Id. § 22-5D-7(b) (2015). 
128 Id. §§ 22-5D-6, 22-5D-10 (2015). 
129 See Trickett Wendler Right to Try Act of 2016, S. 2912, 114th Cong. (2016). 
130 Id. 
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If America truly wants terminal patients to have the right to try, 
Congress must provide clearer guidelines.  The model legislation 
outlined in the following four Sections is not meant to be 
exclusive, but delineates the minimum that should be included in 
a congressional Right to Try statute. 
A. Eligibility Requirements 
First, a list of eligibility requirements is necessary.  At 
minimum, that list should include the following seven 
requirements: (1) The patient has a terminal illness, attested to 
by his or her physician and a consulting physician; (2) The 
patient has considered all other currently approved treatment 
options; (3) The patient has received a recommendation from his 
or her physician for the experimental treatment sought; (4) The 
patient has given written, informed consent for the treatment; 
(5) The patient is unable to participate in a clinical trial within 
one-hundred miles of the patient’s home, or has not been 
accepted into a clinical trial within one week of applying; (6) The 
patient’s physician has determined that the potential risks of 
using the experimental drug do not outweigh the potential 
benefits of using the experimental drug, and that the risks are 
not unreasonable in the context of the patient’s condition; and 
(7) The patient has documentation from his or her physician that 
he or she meets all of the eligibility requirements. 
Requirements number three and seven are standard, 
straightforward requirements.  The patient’s physician must 
recommend, or prescribe, the experimental treatment being 
sought by the patient, and the patient must have documentation 
certified by his or her physician that he or she meets all of the 
eligibility requirements.  These two requirements ensure that a 
patient is acting under the recommendation of a doctor, and not 
on his or her own whim to access new medication. 
Requirement number one should instruct that the patient be 
“terminally ill” as attested to by the patient’s physician and a 
secondary physician.  Often, treating physicians have long-term 
relationships with patients that may, even unintentionally, cloud 
their decision making.131  The second physician’s opinion will 
 
131 Although physicians should act objectively and in the best interests of their 
patients, there is the possibility that a physician’s personal feelings towards 
herpatient will unconsciously direct her medical decisions. 
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(1) ensure that the patient is “terminally ill” for purposes of the 
law and (2) safeguard against overly compassionate treating 
physicians who may be unable to evaluate the situation 
objectively.132 
Eligibility requirement number two, that the patient has 
considered all other currently approved options, is another 
safeguard for the safety of the patient.  Emphasis remains on 
access being the patient’s last viable option. 
Requirement number four, that the patient has provided 
written, informed consent, ensures that a patient understands 
the risks of experimenting with an investigational treatment 
outside the scope of a controlled clinical trial.  Bringing a new life 
to the notion of patient autonomy, the right to try movement 
argues that it should be the patient’s, not the government’s, 
decision whether to try an investigational drug.133  A patient 
cannot competently make such a decision without being fully 
informed about the treatment.  That argument is heightened in a 
right to try situation where the risks are greater and the outlook 
drearier. 
A federal statute should additionally include a specific 
definition of “written, informed consent,” highlighting what must 
be included in the informed consent document.134  This ensures 
that all eligible patients receive enough information to make an 
informed decision. 
Requirement number five mandates that the patient be 
unable to participate in a clinical trial within one-hundred miles 
of his or her home, or has not been accepted into the clinical trial 
within one week of applying.  This requirement counteracts the 
fear that Right to Try laws will undermine the clinical trial 
process by requiring that patients first volunteer to participate in 
a clinical trial before turning to investigational treatment.  
Additionally, this reinforces the law’s intent to be a last resort 
option.  By setting distance and time limitations, this 
requirement also takes into account that patients are often 
ineligible or unable to participate in a clinical trial. 
Requirement number six requires the patient’s physician to 
undertake a risk-benefit analysis.  The physician must 
 
132 This is a common requirement of death by dignity laws throughout the 
country. See, e.g., CAL. HEALTH & SAFETY CODE § 443.6 (2015). 
133 Maxwell, supra note 103, at 3. 
134 See supra notes 60–61 and accompanying text. 
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confidently affirm that the experimental drugs’ potential risks do 
not outweigh its potential benefits to the patient, and that the 
risks are not unnecessary in the context of the patient’s 
condition.  The physician should perform such an analysis using 
information about the drug available to him and his knowledge of 
the patient’s clinical condition.  This protects the patient from 
taking unreasonable risks. 
B. Definitions of Unsettled Terms 
Second, clear definitions should be provided for unsettled 
terms.  “Terminally ill” should be defined as a progressive 
disease or medical condition that is not considered by a treating 
physician to be reversible even with administration of current 
FDA approved and available treatments, and that, without life-
sustaining treatment, will likely result in death within one year, 
or a state of permanent unconsciousness from which recovery is 
unlikely. 
This definition does four important things.  First, it removes 
the requirement that the disease or condition entail “significant 
functional impairment.”  There is no agreed upon definition for 
this term, and the same disease or condition often manifests 
itself differently in one person from the next.135  By removing the 
phrase altogether, the statute avoids identifying which terminal 
patients are suffering from significant functional impairment and 
which are not. 
Second, it requires that the condition not be reversible even 
with the administration of currently approved treatments.  This 
statute must be a last resort option.  If a patient has a chance at 
survival through another approved, and arguably safer, line of 
treatment, the patient should take that option. 
Third, the definition requires that death will likely occur 
within one year.  Once again, this statute is a last resort option.  
There is very minimal knowledge about the safety of Phase One 
drugs.  If a patient can reasonably wait for further safety testing 
of a drug, they should.  This definition does not state that death 
is certain to occur within one year, only that it is likely to occur 
 
135 EXPANDED ACCESS TO INVESTIGATIONAL DRUGS FOR TREATMENT AND USE—
QUESTIONS AND ANSWERS, supra note 93, at 12 (explaining that one individual may 
be denied for expanded access while another individual is approved expanded access 
for the same drug because there may be significant differences in the clinical 
presentation of the disease or condition among the two patients). 
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within one year.  If there is medical reason to believe that the 
patient has a year or less to live, that should be sufficient to 
trigger this statute. 
C. Additional Provisions 
Third, a congressional statute should also address the 
protection and incentives available to induce a manufacturer’s 
voluntary participation.  Manufacturer participation should 
remain voluntary because a federal statute forcing participation 
in distributing a drug that has not yet been legally approved 
undermines the FDA’s approval process. 
To encourage voluntary participation, a provision should be 
included protecting manufacturers who act in good faith with 
reasonable care from liability.  Manufacturers are more likely to 
comply with a statute that does not threaten liability.  The 
requirement that the manufacturer act with good faith and 
reasonable care to invoke the protection at the same time protects 
patients from unscrupulous manufacturers. 
Although a federal statute should encourage manufacturer 
participation, the statute should not prevent the reporting of 
adverse side effects suffered by a right to try patient to the FDA.  
While this may deter voluntary participation from manufacturers 
who have an interest in getting their drugs to the market, the 
FDA’s interest in providing the public with safe drugs, and the 
public’s interest in consuming the safest drugs possible, is 
stronger.  If a drug induces a certain side effect, even a rare side 
effect, the FDA should account for that side effect in the drug’s 
approval process. 
A federal statute should also include a provision specifying 
what a manufacturer may charge for its drug.  Such a provision 
should leave the decision of whether to charge with the 
manufacturer, but limit any charges to the out-of-pocket costs 
related to the drug’s distribution to a specific patient.  Allowing a 
manufacturer to charge may serve as an additional incentive for 
participation.  But, by capping the amount chargeable, 
unscrupulous manufacturers will be unable to over-charge a 
patient.  Additionally, limiting the amount chargeable makes it 
more realistic that economically disadvantaged patients will be 
able to benefit from the law.  This should not be a law for only 
wealthy patients. 
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D. Reconciling State Laws 
Lastly, the noted similarities among state Right to Try laws 
should be adopted into a federal Right to Try statute.  First, the 
definition of an “experimental drug,” which has been adopted in 
state statutes across the country, should also be adopted in the 
federal statute.  An “experimental drug” is defined as “a drug, 
biological product, or device that has successfully completed 
phase one of a clinical trial but has not yet been approved for 
general use by the United States food and drug administration 
and remains under investigation in a United States food and 
drug administration-approved clinical trial.”136  Currently, this is 
the strongest definition available, allowing the earliest access for 
terminal patients possible while still providing some safety-
check. 
Second, physicians’ participation should remain voluntary.  
To encourage participation, a federal statute should ensure that 
physicians, if complying with the statute in good faith and with 
reasonable care, be granted protection from liability and from 
reprimands to their medical licenses.  Physician participation is 
critical for the success of a federal statute and for the safety of 
patients.  Under the watch of a physician, a patient can more 
safely be prescribed and administered experimental drugs. 
CONCLUSION 
Right to Try laws are highly controversial, and for good 
reason.  Notwithstanding the debate between proponents and 
opponents, the right to try movement has only gained momentum 
since its inception, and will likely continue on that path.  If such 
a law is to be adopted federally, the law must be drafted to 
protect the safety of terminal patients and the safety of the 
public health as a whole.  Achieving this balance is possible. 
A federal statute must not rely on new, untested state laws, 
as the Trickett Wendler Act does.  By combining the strongest 
state policies, the FDA’s view, and the arguments of proponents 
and opponents, a federal statute can reach its potential, creating 
a successful and unquestionable “right to try” for terminal 
patients. 
 
 
 
136 See, e.g., COLO. REV. STAT. § 25-45-103(2) (2014). 
